These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

914 related items for PubMed ID: 29193980

  • 1. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF, Kimble TD, Lin FDY, Battucci S, Sniukiene V, Liu JH.
    J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
    [Abstract] [Full Text] [Related]

  • 2. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
    Kroll R, Archer DF, Lin Y, Sniukiene V, Liu JH.
    Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
    [Abstract] [Full Text] [Related]

  • 3. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
    Constantine GD, Simon JA, Pickar JH, Archer DF, Kushner H, Bernick B, Gasper G, Graham S, Mirkin S, REJOICE Study Group.
    Menopause; 2017 Apr; 24(4):409-416. PubMed ID: 27922936
    [Abstract] [Full Text] [Related]

  • 4. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D, Palacios S, Nappi RE, Mueck AO.
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [Abstract] [Full Text] [Related]

  • 5. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.
    Pickar JH, Amadio JM, Hill JM, Bernick BA, Mirkin S.
    Menopause; 2016 May; 23(5):506-10. PubMed ID: 26836245
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
    Archer DF, Goldstein SR, Simon JA, Waldbaum AS, Sussman SA, Altomare C, Zhu J, Yoshida Y, Schaffer S, Soulban G.
    Menopause; 2019 Jan 28; 26(6):611-621. PubMed ID: 30694917
    [Abstract] [Full Text] [Related]

  • 7. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy.
    Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H.
    Menopause; 2009 Jan 28; 16(4):735-41. PubMed ID: 19252451
    [Abstract] [Full Text] [Related]

  • 8. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH.
    Menopause; 2010 Mar 28; 17(2):281-9. PubMed ID: 19779382
    [Abstract] [Full Text] [Related]

  • 9. Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial.
    Simon JA, Archer DF, Kagan R, Bernick B, Graham S, Constantine GD, Mirkin S.
    Menopause; 2017 Sep 28; 24(9):1003-1010. PubMed ID: 28419068
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, BSc AB, Martel C, Vaillancourt M, Balser J, Moyneur É, members of the VVA Prasterone Research Group.
    Menopause; 2018 Nov 28; 25(11):1339-1353. PubMed ID: 30358731
    [Abstract] [Full Text] [Related]

  • 13. TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.
    Simon JA, Kagan R, Archer DF, Constantine GD, Bernick B, Graham S, Mirkin S.
    Climacteric; 2019 Aug 28; 22(4):412-418. PubMed ID: 30862193
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
    De Seta F, Caruso S, Di Lorenzo G, Romano F, Mirandola M, Nappi RE.
    Maturitas; 2021 May 28; 147():34-40. PubMed ID: 33832645
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors.
    Davis SR, Robinson PJ, Jane F, White S, White M, Bell RJ.
    J Clin Endocrinol Metab; 2018 Nov 01; 103(11):4146-4154. PubMed ID: 30239842
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.